On May 12, 2026, the FDA announced it is seeking public feedback on revoking safety approvals for two food additives, BHT and ADA, chemicals found in everything from cereals to yoga mats. This action affects ingredients widely used across the food supply chain, impacting consumer products globally.
The FDA has historically approved and allowed the widespread use of BHT and ADA in food, implying their safety. Now, the agency actively reassesses their safety. It considers revoking those approvals based on current public health risk, challenging past decisions.
Companies reliant on these additives should prepare for potential reformulation requirements. Consumers should anticipate a shift towards 'cleaner' ingredient labels. The FDA adopts a more proactive regulatory stance.
What Are BHT and ADA, and What's Happening Now?
On May 13, 2026, the FDA formally initiated reassessments of butylated hydroxytoluene (BHT) and azodicarbonamide (ADA) by publishing Requests for Information (RFI), as reported by FDA and News Bloomberglaw. This marks the beginning of a process that could lead to the regulatory removal of these widely used substances from the food supply.
A New Era for Food Safety: Prioritizing Public Health
The FDA now prioritizes ingredient safety based on public health risk, not consumer concern, according to Food Dive. A risk-based framework signals a more rigorous, evidence-driven approach. It could impact a broader range of chemicals beyond BHT and ADA. A systematic, internal policy change, not a reactive measure, indicates a lasting transformation in the FDA's approach to food chemical safety.
Decades of Use Under Scrutiny
BHT and ADA have been widely used and long-approved. The FDA's current re-evaluation of their safety, actively seeking feedback on revoking approvals, challenges decades of precedent. The reassessment of long-approved additives demonstrates a regulatory willingness to revisit past decisions, driven by evolving scientific understanding. Their targeting implies no legacy additive is immune from scrutiny under this new risk-prioritization framework.
